- 2023, Volume 81 - Number 2
- Published: June 27, 2023
Stevens-Johnson syndrome/toxic epidermal necrolysis overlap triggered by ethosuximide: a rare pediatric report
Sandra Soares-Cardoso 1, Joana Pimenta 1, Flávia Belinha 2, Manuel Salgado 2, Margarida Rato 3, Cristina Pereira 4, Leonor Ramos 5
1 Department of Pediatrics, Centro Hospitalar Tondela-Viseu, Viseu, Portugal; 2 Pediatric Intensive Care Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 3 Department of Dermatology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal; 4 Department of Neuropediatrics, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 5 Pediatric Hospital, Coimbra Local Health Unit, Coimbra, Portugal
Sandra Soares-Cardoso, Joana Pimenta, Flávia Belinha, Manuel Salgado, Margarida Rato, Cristina Pereira, Leonor Ramos
La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.
*Correspondence: Cristina Pereira, Email not available
Abstract
Introduction: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe and life-threatening mucocutaneous conditions characterized by fever and necrosis of the epidermis. Up to 90% of cases are drug-induced. Antiseizure drugs (ASD) are known to cause SJS, but only a very few ethosuximide-induced SJS cases have been reported in the literature. Case presentation: We report a case of ethosuximide-induced SJS/TEN overlap in a 4-year-old boy, confirmed by patch tests, with improvement with intravenous immunoglobulin (IVIG) and systemic corticosteroid therapy cycle. Conclusion: This case highlights the need to expand knowledge about the optimal treatment strategy for these rare conditions, in addition to supportive treatment.
